Your browser doesn't support javascript.
Progress of the development of anti-COVID-19 drugs
Yaoxue Xuebao ; 58(1):39-51, 2023.
Article in English | Scopus | ID: covidwho-2242734
ABSTRACT
Since the outbreak of the novel coronavirus (SARS-CoV-2) disease COVID-19 (also known as 2019-nCoV) caused by SARS-CoV-2 in the end of 2019, it has spread rapidly in worldwide. Besides developing effective vaccines, it is urgent to develop safe and effective anti-SARS-CoV-2 drugs to fight this disease. Paxlovid, molnupiravir, sotrovimab and bebtelovimab are urgently authorized by FDA have been proved to be effective against Omicron. This manuscript mainly reviews the recent progress of effective inhibitors against the virus in the world, including receptor inhibitors, antibodies, natural product inhibitors, synthetic inhibitors and broad-spectrum antiviral drugs that are effective against other RNA viruses. © 2023, Chinese Pharmaceutical Association. All rights reserved.
Keywords

Full text: Available Collection: Databases of international organizations Database: Scopus Language: English Journal: Yaoxue Xuebao Year: 2023 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: Scopus Language: English Journal: Yaoxue Xuebao Year: 2023 Document Type: Article